DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $1.82M rose 220.6% year over year, ahead of the +126.9% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +33.5% a year.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +220.6% holds above the trailing-twelve-month pace of +126.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.82M+508.5% QoQ
Last fiscal yearDec 2025
$535K+3721.4% YoY
LTMMar 2026
$1.8M+126.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+220.6%——
1 year+3721.4%——
3-year CAGR+33.5%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
535K USD
Year-over-year change
+3721.4%

Accounts Payables vs competitors

How DMAC compares with its peers on the latest reported figures

  • DMAC's LTM Mar 2026 accounts payables of $1.8M is the 4th largest of the 7 companies compared; the peer median is $1.74M.
  • Its year-over-year change of +126.9% is the 2nd highest of 7, against a peer median of -153.3%.
  • Over three fiscal years its annual growth of +33.5% compares with a peer median of -7.4%.
DMAC Competitors Peer median
Accounts Payables for DMAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PROKProKidney Corp.LTM Mar 2026$5.97M -151.4%—672.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$3.38M +7.9%—93.6%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$2.48M -163.4%+27.1%1.1%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$1.8M +126.9%+33.5%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.61M +159.9%-80.7%8.0%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$1.01M -157.4%——
BIOABioAge Labs, Inc.LTM Mar 2026$933K -155.1%-7.4%9.0%
Peer median (excluding DMAC) $1.74M-153.3%-7.4%9.0%

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.59M)(13.68M)(19.38M)(24.44M)(32.77M)
Depreciation & Amortization24K25K30K39K(899K)
Deferred Income Tax00000
Stock-Based Compensation1.56M1.5M1.68M2.09M3.85M
Change in Working Capital(461K)585K93K1.51M675K
Accounts Receivables210K48K(287K)133K(22K)
Inventory00000
Accounts Payables(590K)225K192K14K535K
Other Working Capital(81K)312K188K1.37M162K
Other Non-Cash Items219K53K(1.15M)(1.27M)82K
Operating Cash Flow(12.25M)(11.51M)(18.73M)(22.08M)(29.06M)
Capital Expenditures(22K)(81K)(24K)(25K)(40K)
Acquisitions (Net)00000
Purchases of Investments(69.81M)(45.68M)(69.41M)(50.41M)(59.28M)
Sales of Investments49.3M57.3M51.14M59M57.13M
Other Investing Activities2K0000
Investing Cash Flow(20.54M)11.54M(18.3M)8.56M(2.19M)
Debt Repayment(6K)(6K)(6K)(9K)(10K)
Common Stock Issued29.85M036.85M11.75M44.29M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities244K00256K(400K)
Financing Cash Flow30.09M(6K)36.84M11.99M43.88M
Effect of Forex Changes00000
Net Change in Cash(2.7M)21K(185K)(1.52M)12.62M
Free Cash Flow(12.27M)(11.59M)(18.75M)(22.1M)(29.1M)

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.